EcoDrugPlus

Amine Oxidase Copper Containing 1

Ensembl ID : ENSPTIG00000012449
Gene Symbol: AOC1
2 Cross references
230 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSPTIG00000009712
Gene Symbol: APP
2 Cross references
276 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSPTIG00000013000
Gene Symbol: ACE
2 Cross references
93 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSPTIG00000011825
Gene Symbol: AGTR1
2 Cross references
207 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSPTIG00000009635
Gene Symbol: AGTR2
2 Cross references
191 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSPTIG00000021060
Gene Symbol: APH1A
2 Cross references
137 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSPTIG00000007498
Gene Symbol: APH1B
2 Cross references
190 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSPTIG00000014829
Gene Symbol: APEX1
2 Cross references
212 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSPTIG00000009455
Gene Symbol: ALOX12
2 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSPTIG00000003965
Gene Symbol: ALOX5
1 Cross references
220 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSPTIG00000019272
Gene Symbol: ALOX5AP
2 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSPTIG00000012807
Gene Symbol: AVPR1B
2 Cross references
134 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).